Aimmune Therap (NQ: AIMT )
34.49 USD UNCHANGED Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Stories about Aimmune Therap
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
July 30, 2020
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ...
2 Top Cancer Treatment Stocks To Watch In July
July 14, 2020
These hidden gems have the potential to deliver significant returns to their shareholders over the long run.
Analysts Anticipate PBSM To Hit $29
July 14, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
From ETF Channel
Benzinga's Top Upgrades, Downgrades For July 13, 2020
July 13, 2020
Upgrades ForDarden Restaurants Inc(NYSE: DRI), JP Morgan upgraded the stock from Neutral to Overweight. Darden ...
Why DBV Technologies Is Plunging Today
June 26, 2020
Investors in Aimmune Therapeutics Inc (AIMT) saw new options begin trading this week, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT...
Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?
June 18, 2020
Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?
Sum Up The Parts: IEIH Could Be Worth $34
June 11, 2020
From ETF Channel
Aimmune Therapeutics Inc said on Monday 80% of patients being treated with its drug Palforzia were successfully desensitized to peanut proteins after two years of daily dosing, sending its shares up...
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
May 10, 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares ...
Investors in Aimmune Therapeutics Inc (AIMT) saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay,...
Is Aimmune Therapeutics a Buy?
April 17, 2020
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment.
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 2 months, Aimmune Therapeu has returned 46.77% as of today's recent price of...
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 2 months, Aimmune Therapeu has returned 51.47% as of today's recent price of...
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 2 months, Aimmune Therapeu has returned 54.56% as of today's recent price of...
Bargain Hunters Take Note: Insider Cluster-Buying At AIMT
March 24, 2020
A particularly strong insider buying signal is what we call a "cluster-buy" where three or more different insiders make open market purchases within a short period of one another. At Aimmune...
10 Biggest Price Target Changes For Monday
March 23, 2020
Citigroup cut the price target on The Middleby Corporation (NASDAQ: MIDD) from $115 to $54. Middleby closed at $47.07 on ...
Friday 3/20 Insider Buying Report: AIMT, DX
March 20, 2020
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
The U.S. Food and Drug Administration on Wednesday recommended switching to virtual patient visits instead of in-person monitoring for clinical studies, as signs emerge that the rapid spread of the...
UPDATE 1-Coronavirus begins disrupting clinical trials as companies try containing spread
March 18, 2020
U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as drug developers begin taking preventive measures to contain the...
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
March 18, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
The COVID-19-induced sell-off has taken a toll on stocks across sectors. An analyst at Cantor Fitzgerald presented his take on how ...
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 1 month, Aimmune Therapeu has returned 62.63% as of today's recent price of...